{"entity":{"id":"eu-hta-regulation","kind":"term","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","aka":["HTA Regulation","HTAR","Regulation 2021/2282","joint clinical assessment","joint clinical assessments","JCA","JCAs","joint scientific consultation","Member State Coordination Group on HTA","HTACG"],"tldr":"From January 2025 every new cancer medicine in the EU gets one shared assessment of how well it works compared with existing treatments, done jointly by member states, so that each country's payer no longer repeats the clinical review, though each still decides on price.","summary":"European Union, regulation. Regulation (EU) 2021/2282 on health technology assessment of 15 December 2021 applies from 12 January 2025, first to medicines for cancer and advanced therapy medicinal products, then to orphan medicines from January 2028 and all new medicines from January 2030. Primary text: EUR-Lex; the Commission's HTA pages carry the implementing acts and the Coordination Group's methods.\n\nWhat it does: when a medicine enters the centralised authorisation procedure, the Member State Coordination Group on HTA scopes the questions each country needs answered (populations, comparators, outcomes, the 'PICO' scope) and produces a joint clinical assessment report on relative effectiveness and its uncertainty, published shortly after the Commission's authorisation decision. Member states must give it 'due consideration' but keep national responsibility for appraisal, pricing and reimbursement. Joint scientific consultations let developers ask for advice on trial design early, and horizon scanning identifies coming technologies.\n\nWhy it matters for oncology and the arguments: cancer medicines are the first cohort precisely because they are where national assessments diverged most and where the gap between approval and reimbursement is longest. Industry fears the consolidated PICO scopes will demand many comparisons that a pivotal trial could not have anticipated, and that a critical joint report will follow a product into every negotiation; payers see one rigorous assessment instead of repeated work; patient groups want faster, more even access across richer and poorer member states. The first oncology joint assessments began in 2025 and their timing relative to national decisions is the metric to watch.","asOf":"2026-09-17","links":[{"label":"EUR-Lex: Regulation (EU) 2021/2282","url":"https://eur-lex.europa.eu/eli/reg/2021/2282/oj"},{"label":"European Commission: health technology assessment","url":"https://health.ec.europa.eu/health-technology-assessment_en"}],"tags":["law","eu"],"related":["hta","icer-value-assessment","nice-methods","amnog","eu-regulation-726-2004","eu-pharma-package","european-health-data-space","inflation-reduction-act","qol-pro"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ema","g-ba-iqwig","has-france"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-regulatory-fragmentation","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/eu-hta-regulation/","neighbours":{"term":[{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/"},{"id":"eu-pharma-package","kind":"term","name":"EU pharmaceutical package reform (2023 proposal)","route":"/terms/eu-pharma-package/"},{"id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/"},{"id":"france-early-access","kind":"term","name":"France: early access (accès précoce), formerly ATU","route":"/terms/france-early-access/"},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/"},{"id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/"},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/"},{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/"},{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/"},{"id":"eu-regulation-726-2004","kind":"term","name":"Regulation (EC) No 726/2004: the EU centralised procedure","route":"/terms/eu-regulation-726-2004/"}],"institution":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/"},{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/"},{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","route":"/institutions/has-france/"}],"bottleneck":[{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}]}}